ADV: Stock-2000 Finds Stock for the Next Millennium!!!

best-stock at best-stock at
Wed Jan 20 09:40:11 PST 1999

* From the T10 Reflector (t10 at, posted by:
* best-stock at
To our dedicated subscribers, we thank you for believing in us and hope you were profitable with our last profile. To our new subscribers, we hope you enjoy and prosper in the future.

Visit for for full details and the full Wall Street Journal Story.

We are reiterating our previous profile of D-Lanz Development Group, Inc (DLNZ). Recent developments have caused us to revisit this dynamic and exciting situation.

The reasons we are so excited is because of the encouraging press releases that have come out concerning the company. DLNZ is about to increase their territory and with this increase the BreastCare device will become available to millions of additional potential buyers. We believe this should have a major impact to the bottom line. For full details please read the following profile, an article from the Wall Street Journal (01-05-99) and additional comments by the CEO of D-Lanz Development Group, Mr. Roger Fidler.

Here is what impresses us. D-Lanz Development Group (herein after referred to as "DLNZ" or "the Company") has a non-invasive product already approved by the FDA that every woman in the world can obtain to detect breast abnormalities (e.g. cancer)! Rather than undergoing a mammography, a primary care physician, gynecologist or other medical specialist can insert this device, (sold internationally under the trademark BreastCare and in the United States as BreastAlert), inside a woman's brassiere where it is left for a period of 15 minutes If the device indicated unilateral breast thermal activity, the physician is alerted to the possibility of a physiological condition including thermally active cancer.

Breast cancer, one of the most common cancers among women, is currently the leading cause of death among women between the ages of 25 and 54, in the United States. This suggests that a tremendous market awaits this product as it becomes available, not only in American but other countries as well. We project that overseas markets will compound demand for the product accordingly. In 1997, DLNZ acquired an exclusive license to market its BreastCare indicator in Chile and Singapore. It has recently been given authority to market in South Korea. Using this as a stepping stone, the company eventually intends to market this device in other eastern countries. We believe that in the coming months, women all around the globe will be attracted to this non-invasive method to detect breast cancer and other abnormalities.

In the United States, breast cancer screening is generally recommended as a routine part of preventive health care for more than 90 million women. In addition, industry sources estimate that approximately 11.3 million mammograms and 800,000 surgical biopsies were performed in the U.S. in 1994 (the last year for which such data is available from the Center for Disease Control) so as DLNZ begins to distribute products, we believe demand will rapidly increase, consequently boosting revenue and earnings to impressive levels.

In conclusion, we are impressed with the results of the research done at Sloan-Kettering Hospital, Georgetown University School of Medicine, Anderson Hospital and Tumor Institute, Brottman Memorial Hospital (UCLA), and Guttman Cancer Diagnostic Institute.

Investor Relations
Contact: Roger Fidler
Chief Executive Officer
Phone (201) 457-1221


D-LANZ Development Group Inc. (DLNZ), a development stage company, commenced business activities as a partnership in 1947 and was incorporated in 1952 under the name Osrow Products Company, Inc. In 1990,the company amended its certificate of incorporation to change its name to D-Lanz Development Group Inc. In September of 1997 D-Lanz Development Group acquired the assets of Health Technologies International, Inc. (HTI).

It was through this acquisition that the company acquired exclusivity in Chile and Singapore to market the breast thermal activity indicator ("BTAI") device that is now called BreastCare.

BreastCare is a primary breast cancer screening device, sold in the United States under the trade name BreastAlert by HumaScan, Inc. D-Lanz Development Group licenses marketing rights for BreastCare from Scantek Medial, Inc of Denville, New Jersey for the countries of Chile, Singapore and (anticipated shortly) South Korea.


BreastCare is non-invasive, easy to use low-cost indicator that has proven to be an excellent adjunctive test used by primary care physicians, gynecologists and other medical specialists. As part of a breast disease monitoring program,

BreastCare should be used in some combination with breast self-examination, palpation and (depending on a patient's age, family history and other factors) mammography and other established clinical procedures, including ultrasound and/or biopsy. An important feature of the BreastCare is that the results are immediately available (often within 15 minutes) to the physician while the patient is "on site" at the point of care in the physicians office, clinic, hospital and/or mammography center. In Chile and Singapore, the woman can obtain the results at home since the product can be sold over the counter through drug stores. If BreastCare indicated unilateral breast thermal activity (i.e. in one breast only), the physician is alerted to the possibility of an "unknown" physiological condition that could include thermally active cancer.


The original device was patented in 1980 by Dr. Zsigmond L. Sagi who assigned the patents to a private company called BCSI Laboratories, Inc. which shortly thereafter was acquired by Faberge. In 1984, following the original devices 510(k), (FDA authorization to market), Faberge constructed a plant to commence commercial production. In 1985, McGregor Industries acquired Faberge and discontinued many Faberge products including the original breastdevice. In 1986, DR Sagi formed Scantek Medical Corp. and purchased the devices patent rights (including the regulatory clearances) from McGregor Industries. In 1995 Scantek granted an exclusive license to HumaScan to manufacture and market the device in the U.S. and Canada under the trademark name of BreastAlert. In 1997 D-Lanz became the licensed marketer of the device in Chile and Singapore under the trademark name BreastCare.


Primary competition for BreastCare is mammography. The company has not applied for any governmental approval of its product in the territories of its exclusive license however, strong indications are that since the product was approved for use in the United States, its registration in those territories will proceed rapidly. Currently, Scantek Medical manufactures BreastCare for the company on a cost plus basis. Sandell S.A., which distributes BreastCare for Scantek throughout South America through a system of sub-distributors, has agreed to distribute in Chile on behalf of D-Lanz. The Company Anticipates that Grupo Grifols, S.A., an international distributor of a variety of medical products will distribute in Chile for Sandell through its sales and distribution company G.G. Chile. Formed in 1940 and owned 50/50 by Spanish shareholders and Green Cross Corporation, Grupo Grifols has over 1,000 employees and annual revenues of over 20 billion pesetas.


For over thirty years, breast cancer detection has been dominated in technically advanced countries by mammography. In less economically developed areas of the world, self-examination and professional palpation are extensively used. The basic problem with mammography is one of capital cost with equipment running from hundreds of thousands of dollars in the millions.

This fact, along with the costs associated with expert reading of mammograms, results in costs in the United States of between $100 and $200 per reading. In less advantaged countries, the price is lower, but still high in comparison with local per capita income. For example, according to various sources, a mammogram in South Korea costs between $30 and $40 (US).  Whole BreastCare is not expected to exceed the $20 range.

In addition to cost, mammography requires expert reading, usually done by a physician or trained specialist. The reading process itself is subject to a high degree of variability and introduces a significant source of error.  These errors are compounded by problems associated with breast tissue density.

This is the cause of frequently reported controversy as to the age at which mammography is recommended. Clearly, women over 50 are almost always advised to have an annual or biennial mammogram. However, for women between the ages of 40 and 50, there is widespread disagreement as to the effectiveness of mammograms. Below the age of 40, mammograms are not recommended due to the difficulty in distinguishing between tumor tissue and young healthy dense breast tissue.


As breast cancer cells multiply, excessive heat is often generated. This heat is conveyed to the surface of the breast, resulting in the temperature of the skin of a particular area of one breast being elevated between 2 degrees and 6degrees Fahrenheit in comparison to the temperature of the same area of the other breast. Simply explained, BreastCare permits the measurement and comparison of temperature variances between mirror images of each breast.

BreastCare consists of two soft disposable pads, each of which has three wafer-thin segments containing columns of "heat-sensitive chemical" sensor dots that change color from blue to pink, reflecting an 8.5 degree temperature range between 90 degrees to 98.5 degrees Fahrenheit. This device is placed over a woman's breast inside her bra for a period of 15 minutes. An elevated temperature differential of two degrees Fahrenheit (or more) between each breast, in the same location, may indicate either thermal (metabolic) active breast cancer cells certain types of heat-generating breast disease.

Because of its digitized readability, which is not dependent on tissue density, BreastCare is very effective with younger women. It provides a relatively easy method of reading and interpreting the results, rendering it more useful in an "over-the-counter" application in those foreign countries where such distribution is allowed.


On August 20, 1998, the company announced that it had entered into a distribution agreement with Sandell corp. S.A. to distribute BreastCare in Chile. Mr. Roger Fidler, the Company's president stated "This agreement should result in the first revenues into our company before the end of this year. It is the first step toward achievement of our primary corporate goal of establishing distribution throughout our countries before year end."


Mr. Fidler has been the sole Director, President, Chief Executive and Financial Officer of the company since September 1989. He will serve until the next annual meeting scheduled for May 1999, or until his successor is elected and qualified. Since 1983, Mr. Fidler has been engaged in the private practice of law. From 1994 to the present, he also has been president of PPA Technologies, Inc, a private specialty chemicals company. From 1994 to 1997, Mr. Fidler was also President of Health Technologies International, Inc. a private medical device company that in 1997 was subsequently merged into DLNZ. Mr. Fidler has a MA from University of South Carolina. He also has a Masters degree in Physics from University of Illinois.

Mr. Hait has served as Secretary of the corporation since November 1997 and will continue to serve until his successor is elected and qualified. Mr. Hait has worked as an attorney in Mr. Filder's law practice since May of 1997. Prior to that, from 1994 to 1996, Mr. Hait was employed as a computer programmer at Isis Corporation of Oakland, NJ. During 1993, Mr.Hait worked as a help desk LAN Technician at MDY Advanced Technologies of Fair Lawn, NJ. Prior to 1993, for approximately one year, he occupied the same capacity for Viacom in New York City.



Dow Jones News Service via DowVision

GLEN ROCK, NJ (Dow Jones) - D-Lanz Development group, Inc, (DLNZ) was given permission by Scantek Medical Inc. (SKML) to negotiate with Indonesian and Malaysian distributors to supply Scantek's Breastcare device in those countries.

scantek holds the worldwide rights to the device, which detects abnormalities in the breast, including breast cancer.

A D-Lanz spokesman said the company will receive unspecified monetary fees from the distributors.

"There is no obligation to pay a fee to Scantek," The spokesman added, D-Lanz plans to distribute the device in Indonesia and Malaysia in the second calendar quarter of this year.

In a press release Friday, the company said Breastcare gross margins are expected to be more than 50% of sales.

D-Lanz sales figures weren't immediately available.



Copyright 1999 Dow Jones & Company, Inc.

Glen Rock, New Jersey
December November 6, 198-1:30pm EST

D-Lanz Development Group, Inc. (DLNZ-OTC Bulletin Board) announced today that it had been given permission by Scantek medical, inc. to negotiate with Indonesian and Malaysian distributors to distribute its Breastcare device in Indonesia and Malaysia. Roger Fidler, President of D-Lanz stated, "the net effect of the expansion of our distribution rights into Indonesia and Malaysia is to once again more than triple the number of women to whom DDG may distribute Breastcare.  Indonesia alone has a population of over two hundred million persons." with rights in Chile, Singapore, South Korea, Indonesia and Malaysia, DDG will be serving a relevant female population of about one hundred million.  Breastcare gross margins are expected to exceed fifty percent (50%) of sales according to Mr. Fidler. Breastcare is the trade name for Scantek Medical's revolutionary new method of breast abnormality, including breast cancer detection which DDG licenses.

For further information
Contact Roger Fidler, CEO
(201) 457-1221

****** DISCLAIMER ******

This material is being provided by Stock-2000, an electronic newsletter paid by the issuer for publishing the information contained in this report.  D-Lanz Development Group, Inc. has paid a consideration of 15,000 shares of common stock of D-Lanz Development Group, Inc. to Stock-2000 as payment for the publication of the information contained in this report.  Stock-2000 and its affiliates have agreed not to sell the common stock received as payment for its services until December 7, 1998, which date is 15 days from the initial dissemination of this report. After such date, Stock-2000 may sell such shares. Because Stock-2000 is paid for its services, there is an inherent conflict of interest in Stock-2000's statements and opinions and such statements and opinions cannot be considered independent. The information contained in this publication is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. Stock-!
 2000 makes no representation or wa
rrant relating to the validity of the facts presented nor does Stock-2000 represent or warrant that all material facts necessary to make an investment decision are presented above. All statements of opinions are those of Stock-2000. Stock-2000 relies exclusively on information gathered from public filings on featured companies, as well as, in certain circumstances, interviews conducted by Stock-2000 of management of featured companies. Investors should not rely solely on the information contained in this publication. Rather, investors should use the information contained in this publication as a starting point for conducting additional research on the featured companies in order to allow the investor to form his or her own opinion regarding the featured companies. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. Stock-2000 is not a registered investment adviser, broker or a dealer. Investment in th!
 e companies reviewed is speculativ
e and extremely high-risk and may result in the loss of some or all of any investment made in D-Lanz Development Group, Inc. This publication contains forward-looking statements that are subject to risk and uncertainties that could cause results to differ materially from those set forth in the forward-looking statements. These forward-looking statements represent the judgment of D-Lanz Development Group, Inc. as of the date of this publication. The Company disclaims any intent or obligation to update these forward-looking statements.

* For T10 Reflector information, send a message with
* 'info t10' (no quotes) in the message body to majordomo at

More information about the T10 mailing list